The Pertussis Serological Potency Test. Collaborative study to evaluatereplacement of the Mouse Protection Test

A van der Ark1, I van Straaten-van de Kappelle, R M Olander

  • 1National Institute of Public Health and Environmental Protection, Bilthoven, The Netherlands.

Insights

The Pertussis Serological Potency Test (PSPT) offers a reliable in vitro alternative to the Mouse Protection Test (MPT) for assessing pertussis vaccines. This study confirms PSPT

Area of Science:

  • * Immunology
  • * Vaccinology
  • * Microbiology

Background:

  • * The Mouse Protection Test (MPT) is the standard for pertussis vaccine potency testing.
  • * An in vitro alternative, the Pertussis Serological Potency Test (PSPT), was developed.
  • * PSPT assesses the humoral immune response against Bordetella pertussis.

Purpose of the Study:

  • * To evaluate the relevance and reliability of the PSPT in a collaborative study.
  • * To compare PSPT with the established MPT.
  • * To assess the performance of the 18323-whole cell ELISA (WCE) assay.

Main Methods:

  • * A collaborative study involving five laboratories.
  • * Three phases: pilot study of 18323-WCE, Phase I for precision, Phase II for comparative analysis.
  • * Assessed intra-assay, inter-assay, and inter-laboratory precision of 18323-WCE.

Main Results:

  • * Significant differences in absorbance and antibody concentrations were observed between laboratories.
  • * Despite variations, antibody ranking in the 18323-WCE assay showed good inter-laboratory correlation.
  • * Vaccine potencies estimated by PSPT and MPT did not differ significantly; PSPT demonstrated higher reproducibility.

Conclusions:

  • * The Pertussis Serological Potency Test (PSPT) is a valid and reliable in vitro method for estimating pertussis whole cell vaccine (WCV) potencies.
  • * The 18323-WCE assay is easy to perform and provides reliable potency testing.
  • * PSPT offers improved reproducibility and reduced re-testing compared to MPT.

Related Concept Videos